A Dose Ranging Phase I/Ii Trial of the Von Willebrand Factor Inhibiting Aptamer ARC1779 in Patients With Congenital Thrombotic Thrombocytopenic Purpura
Thrombosis and Haemostasis - Germany
doi 10.1160/th11-02-0069
Full Text
Open PDFAbstract
Available in full text
Categories
Date
January 1, 2011
Authors
Publisher
Georg Thieme Verlag KG